NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
02/17/2026
Back to search
Official data from USPTO
ONECLINICAL INTEGRATED CLINICAL ENTERPRISE
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
30
Latest update
03/10/2026
Classification
Registered
Trademark type
Combined
Nice classes
9, 42
Filing date
09/04/2017
Registration date
04/09/2019
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
02/17/2026
Last transaction
03/10/2026
Responsible office
United States Patent and Trademark Office
Status code
705
Official register
Principal Register
Filing basis
Intent to use
Drawing code
5
Owner type
03
Owner location
Portsmouth, Hampshire, GB
Examiner
KEATING, MICHAEL P
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the term "ONECLINICAL" above the wording "INTEGRATED CLINICAL ENTERPRISE", with "ONE" in green, "CLINICAL" in blue and the words "INTEGRATED CLINICAL ENTERPRISE" in blue.
Holders and representatives
Holders
NAVITAS LIFE SCIENCES HOLDINGS LIMITED
Representatives
Rebecca Liebowitz VENABLE LLP
Technical classification
Nice Classes
Class 9Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 9
Computer software for use in administering clinical drug and medical device trials and submitting documents as part of clinical drug trial approval processes; Computer software for use in pharma and medical device product information management and to address regulatory requirements for pharma and medical device product information management; computer software platforms for use in pharma and medical device product information management and to address regulatory requirements for pharma and medical device product information management
Class 42
scientific and technological services and research and design relating theretoscientific researchpharmaceutical drug development servicestechnology research in the field of pharmaceuticalsproviding temporary use of on line non-downloadable computer software for submitting documents as part of for clinical drug trial approval processes and for use in pharma and medical device product information management and to address regulatory requirements for pharma and medical device product information management; advisory and consultancy services in the field of biotechnology; advisory services relating to scienceconsulting services in the field of pharmacovigilancebiopharmaceutical and biotechnology research and consulting services relating to pharma and medical device product information management for pharma and medical device product information management; industrial analysis and research servicesindustrial research in the field of medical devices; advisory and consultancy services relating to computer networking applications software
Publications
History of USPTO decisions and trademark events.
30 publications found
C15P
REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
02/17/2026
EROP
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
02/17/2026
PR23
POST REGISTRATION ACTION MAILED - SEC. 8 & 15
08/14/2025
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
08/14/2025
E815
TEAS SECTION 8 & 15 RECEIVED
04/09/2025
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
04/09/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
04/09/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/22/2019
PUBO
PUBLISHED FOR OPPOSITION
01/22/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/02/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/17/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/17/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/17/2018
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
12/17/2018
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
06/28/2018
GNFR
FINAL REFUSAL E-MAILED
06/28/2018
CNFR
FINAL REFUSAL WRITTEN
06/28/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/15/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/15/2018
ALIE
ASSIGNED TO LIE
06/14/2018
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
06/01/2018
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
12/12/2017
GNRT
NON-FINAL ACTION E-MAILED
12/12/2017
CNRT
NON-FINAL ACTION WRITTEN
12/12/2017
DOCK
ASSIGNED TO EXAMINER
12/06/2017
TAEA
TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED
10/31/2017
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
10/31/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/11/2017
NWAP
NEW APPLICATION ENTERED
09/07/2017
Continuous trademark protection
Get notified about every new filing that threatens ONECLINICAL INTEGRATED CLINICAL ENTERPRISE or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.